Hepatotoxicity to sodium valproate: a review.

P. Powell‐Jackson,J. Tredger,R. Williams
DOI: https://doi.org/10.1136/gut.25.6.673
IF: 24.5
1984-06-01
Gut
Abstract:Since 1978 a number of reports have indicated a possible association between sodium valproate therapy and the occurrence of hepatitis. In this review we have analysed, with particular reference to the clinical presentation, course and coadministration of other drugs, the 42 cases with fatal hepatitis either known to the manufacturers or reported elsewhere,'11 and the more frequent cases with milder forms of hepatitis varying in severity from a transient rise in aminotransferase activities to symptomatic cases with reversible hepatic failure.12-30 We have also considered the three reported cases with a Reye's-like syndrome2 9 31 and 22 instances of hyperammonaemia32-38 which is usually found in the absence of clinical evidence of hepatic injury but can easily be confused with fulminant hepatic failure. Possible mechanisms for the hepatotoxicity in relation to recently reported experimental work and the value of liver function tests in monitoring valproate therapy are also considered.
What problem does this paper attempt to address?